{"id":58477,"date":"2023-11-26T19:05:10","date_gmt":"2023-11-26T18:05:10","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\/"},"modified":"2023-11-26T19:05:10","modified_gmt":"2023-11-26T18:05:10","slug":"median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\/","title":{"rendered":"Median Technologies Announces Rebranding of iBiopsy\u00ae, Changes Name to eyonis\u2122"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nThe Company announces a new identity for its iBiopsy\u00ae AI\/ML tech-based suite of software as medical devices (SaMD), and business unit.<\/li>\n<li>\niBiopsy\u00ae becomes eyonis\u2122.<\/li>\n<li>\neyonis\u2122 brand visual identity is unveiled today at the Radiological Society of North America (RSNA) 2023 Annual Meeting, taking place in Chicago, IL, USA, Nov. 26-30.<\/li>\n<\/ul>\n<p>SOPHIA ANTIPOLIS, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20231126347438\/en\/1343975\/5\/Median_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20231126347438\/en\/1343975\/21\/Median_RGB.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20231126347438\/en\/1343975\/5\/Median_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20231126347438\/en\/1343975\/22\/Median_RGB.jpg\"><\/a><\/p>\n<p>\nMedian Technologies (Paris:ALMDT) today unveils a new identity, including a new name, logo, tagline for<strong> <\/strong>its iBiopsy\u00ae AI\/ML tech-based suite of software as medical devices (SaMD) and business unit, as part of an extensive rebranding initiative.<\/p>\n<p>\nStarting today, the Company has officially rebranded iBiopsy\u00ae to the new name of eyonis\u2122. This rebranding marks a significant milestone in Median\u2019s corporate trajectory and underscores the Company\u2019s unwavering dedication to delivering cutting-edge Software as Medical Devices (SaMD) to the radiology market. The new brand identity fully aligns with Median\u2019s vision for the future, and the path the Company is charting.<\/p>\n<p>\nMedian\u2019s new brand name eyonis\u2122 brings \u201cEye\u201d at the forefront, to create a connection to visual imaging then combined with \u201cOnis\u201d which takes it to power, and efficacy. This concept resonates with Median\u2019s mission, and therefore, the new eyonis\u2122 brand tagline is &#8220;Catching the Unseen\u201d, that perfectly encapsulates Median\u2019s commitment to harnessing the power of medical images combined with the strength of Artificial Intelligence to bring previously unseen insights to light with efficacy in order to enable better and earlier diagnosis of patients.<\/p>\n<p>\n&#8220;<i>As a reflection of our commitment to bringing the best of AI\/ML tech-based methodologies to software as medical devices to help fight cancers, we embark on a transformative journey from iBiopsy\u00ae to eyonis\u2122, a new brand name with an etymology linked to vision, power, and efficacy. As we step into these new horizons, we carry with us the rich heritage and brand equity of iBiopsy<\/i><i>\u00ae, and we stand poised to capitalize on our reputation with eyonis\u2122 as a renewed vision, to build on the foundation of excellence that has defined us and will redefine benchmarks of success in the early diagnosis of cancers,<\/i>&#8221; Thomas Bonnefont, COO and CCO of eyonis\u2122 said.<\/p>\n<p>\neyonis\u2122 brand visual identity is unveiled today at the opening of the Radiological Society of North America (RSNA) 2023 Annual Meeting, taking place in Chicago, IL, USA. Median\u2019s teams will be at booth #4465, Level 3 South Hall (AI showcase) to present the latest development of eyonis\u2122, Median\u2019s AI\/ML tech-based suite of Software as Medical Devices. eyonis\u2122 will be the commercial name of Median\u2019s SaMD portfolio in the US and Europe once the Company receives the 510K clearance from the FDA and the CE marking in Europe.<\/p>\n<p>\n<strong>About Median Technologies:<\/strong><b> <\/b>Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and eyonis\u2122, our AI\/ML tech-based suite of software as medical devices (SaMD), help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.<\/p>\n<p>\nFounded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label \u201cInnovative company\u201d by the BPI and is listed on Euronext Growth market (Paris). FR0011049824\u2013 ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mediantechnologies.com%2F&amp;esheet=53862333&amp;newsitemid=20231126347438&amp;lan=en-US&amp;anchor=www.mediantechnologies.com&amp;index=1&amp;md5=98ba0bbdd1de9e0379970f957250fa2a\" rel=\"nofollow noopener\" shape=\"rect\">www.mediantechnologies.com<\/a><\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Median Technologies<\/b><br \/>Emmanuelle Leygues<br \/>\n<br \/>Head of Corporate Marketing &amp; Financial Communications<br \/>\n<br \/>+33 6 10 93 58 88<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#x6c;&#x74;&#111;&#x3a;e&#109;&#x6d;&#97;&#x6e;u&#101;&#x6c;l&#x65;&#46;&#108;&#x65;y&#x67;&#x75;&#101;&#x73;&#64;&#109;&#x65;&#100;&#x69;a&#110;&#x74;&#101;&#x63;h&#110;&#x6f;l&#x6f;&#x67;&#105;&#x65;s&#46;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">emm&#97;&#110;&#117;&#x65;&#x6c;&#x6c;&#x65;&#x2e;&#x6c;eyg&#117;&#101;&#115;&#64;&#x6d;&#x65;&#x64;&#x69;&#x61;&#x6e;tec&#104;&#110;&#111;&#x6c;&#x6f;&#x67;&#x69;&#x65;&#x73;&#46;co&#109;<\/a><\/p>\n<p>\n<b>Press &#8211; ALIZE RP<\/b><br \/>Caroline Carmagnol<br \/>\n<br \/>+33 6 64 18 99 59<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#97;&#x69;l&#116;&#x6f;&#x3a;m&#101;&#x64;&#x69;a&#110;&#x40;&#x61;l&#105;&#x7a;&#x65;r&#112;&#x2e;&#x63;o&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6d;&#101;d&#x69;&#97;n&#x40;&#97;l&#x69;&#122;e&#x72;&#112;&#46;&#x63;&#x6f;m<\/a><\/p>\n<p>\n<b>Investors &#8211; ACTIFIN<\/b><br \/>Ghislaine Gasparetto<br \/>\n<br \/>+33 6 21 10 49 24<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#105;&#x6c;&#x74;o:&#103;&#103;&#x61;&#x73;pa&#114;&#101;&#x74;&#x74;o&#64;&#97;&#x63;&#x74;&#x69;f&#105;&#110;&#x2e;&#x66;&#x72;\" rel=\"nofollow noopener\" shape=\"rect\">&#x67;&#x67;&#97;s&#x70;&#x61;&#x72;&#101;t&#x74;&#x6f;&#x40;&#97;c&#x74;&#x69;&#x66;&#105;n&#x2e;&#x66;&#x72;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The Company announces a new identity for its iBiopsy\u00ae AI\/ML tech-based suite of software as medical devices (SaMD), and business unit. iBiopsy\u00ae becomes eyonis\u2122. eyonis\u2122 brand visual identity is unveiled today at the Radiological Society of North America (RSNA) 2023 Annual Meeting, taking place in Chicago, IL, USA, Nov. 26-30. SOPHIA ANTIPOLIS, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-58477","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Median Technologies Announces Rebranding of iBiopsy\u00ae, Changes Name to eyonis\u2122 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Median Technologies Announces Rebranding of iBiopsy\u00ae, Changes Name to eyonis\u2122 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The Company announces a new identity for its iBiopsy\u00ae AI\/ML tech-based suite of software as medical devices (SaMD), and business unit. iBiopsy\u00ae becomes eyonis\u2122. eyonis\u2122 brand visual identity is unveiled today at the Radiological Society of North America (RSNA) 2023 Annual Meeting, taking place in Chicago, IL, USA, Nov. 26-30. SOPHIA ANTIPOLIS, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-26T18:05:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20231126347438\/en\/1343975\/21\/Median_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Median Technologies Announces Rebranding of iBiopsy\u00ae, Changes Name to eyonis\u2122\",\"datePublished\":\"2023-11-26T18:05:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\\\/\"},\"wordCount\":654,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231126347438\\\/en\\\/1343975\\\/21\\\/Median_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\\\/\",\"name\":\"Median Technologies Announces Rebranding of iBiopsy\u00ae, Changes Name to eyonis\u2122 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231126347438\\\/en\\\/1343975\\\/21\\\/Median_RGB.jpg\",\"datePublished\":\"2023-11-26T18:05:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231126347438\\\/en\\\/1343975\\\/21\\\/Median_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231126347438\\\/en\\\/1343975\\\/21\\\/Median_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Median Technologies Announces Rebranding of iBiopsy\u00ae, Changes Name to eyonis\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Median Technologies Announces Rebranding of iBiopsy\u00ae, Changes Name to eyonis\u2122 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\/","og_locale":"en_US","og_type":"article","og_title":"Median Technologies Announces Rebranding of iBiopsy\u00ae, Changes Name to eyonis\u2122 - Pharma Trend","og_description":"The Company announces a new identity for its iBiopsy\u00ae AI\/ML tech-based suite of software as medical devices (SaMD), and business unit. iBiopsy\u00ae becomes eyonis\u2122. eyonis\u2122 brand visual identity is unveiled today at the Radiological Society of North America (RSNA) 2023 Annual Meeting, taking place in Chicago, IL, USA, Nov. 26-30. SOPHIA ANTIPOLIS, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\/","og_site_name":"Pharma Trend","article_published_time":"2023-11-26T18:05:10+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20231126347438\/en\/1343975\/21\/Median_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Median Technologies Announces Rebranding of iBiopsy\u00ae, Changes Name to eyonis\u2122","datePublished":"2023-11-26T18:05:10+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\/"},"wordCount":654,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20231126347438\/en\/1343975\/21\/Median_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\/","url":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\/","name":"Median Technologies Announces Rebranding of iBiopsy\u00ae, Changes Name to eyonis\u2122 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20231126347438\/en\/1343975\/21\/Median_RGB.jpg","datePublished":"2023-11-26T18:05:10+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20231126347438\/en\/1343975\/21\/Median_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20231126347438\/en\/1343975\/21\/Median_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Median Technologies Announces Rebranding of iBiopsy\u00ae, Changes Name to eyonis\u2122"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=58477"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58477\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=58477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=58477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=58477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}